- ￥22
- ProSci
- 美国
- PSI-33-994-100ug
- 2025年07月08日
- Flow, IF, IHC-P
- 小鼠
企业认证
相关产品推荐更多 >
Cyclin Dependent Kinase Inhibitor 1C Phospho-Thr310 (CDKN1C pT310) Antibody/Cyclin Dependent Kinase Inhibitor 1C Phospho-Thr310 (CDKN1C pT310) Antibody/Cyclin Dependent Kinase Inhibitor 1C Phospho-Thr310 (CDKN1C pT310) Antibody
询价
Rabbit polyclonal antibody to human Mitofusin 2 (601-757): Affinity purified/Rabbit polyclonal antibody to human Mitofusin 2 (601-757): Affinity purified/Rabbit polyclonal antibody to human Mitofusin 2 (601-757): Affinity purified
询价
PERK 抗体（pThr892）|PERK Antibody (pThr892)
询价
Tetraspanin 12 (TSPAN12) Antibody/Tetraspanin 12 (TSPAN12) Antibody/Tetraspanin 12 (TSPAN12) Antibody
询价
Annexin V, R-PE|Annexin V, R-PE
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant human protein was used as the immunogen for the VCAM-1 antibody.
- 保存条件：
Aliquot and Store at 2-8℃
- 保质期：
1年
- 级别：
科研级别
- 库存：
100
- 供应商：
艾美捷科技
- 宿主：
小鼠
- 应用范围：
Flow, IF, IHC-P
- 抗体英文名：
VCAM-1 Antibody [CDLA106]
- 抗体名：
VCAM-1 Antibody [CDLA106]
- 规格：
100ug
VCAM-1 抗体 [CDLA106]，VCAM-1 Antibody [CDLA106]，VCAM-1 抗体 [CDLA106],VCAM-1 Antibody [CDLA106]
产品名称：VCAM-1 抗体 [CDLA106]-VCAM-1 Antibody [CDLA106]
产品货号：PSI-33-994-100ug
产品规格：100ug
背景资料：Vascular cell adhesion molecule-1 (VCAM-1), also called L1CAM and CD106, is important in cell-cell recognition. Appears to function in leukocyte-endothelial cell adhesion. Interacts with integrin alpha-4/beta-1 (ITGA4/ITGB1) on leukocytes, and mediates both adhesion and signal transduction. The VCAM1/ITGA4/ITGB1 interaction may play a pathophysiologic role both in immune responses and in leukocyte emigration to sites of inflammation. [UniProt]
保存建议：VCAM-1 抗体 [CDLA106]-VCAM-1 Antibody [CDLA106]Aliquot and Store at 2-8℃
应用类型：Flow, IF, IHC-P
点击：VCAM-1 抗体 [CDLA106]-VCAM-1 Antibody [CDLA106]查看更详细产品说明，更多应用、储存、价格、货期等信息请垂询艾美捷科技有限公司。更多ProSci公司特色试剂盒、特色抗体以及特色试剂等产品评论，请点击查看艾美捷特色产品中心。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Nature 综述导读：FDA 批准第 100 个抗体药物！抗体药物的研究方向在哪里？
批准了第 50 种抗体，距离第一个抗体已经过去了 29 年。2021 年 4 月，随着葛兰素史克 PD1 阻断剂 dostarlimab 的批准，抗体药物仅用了 6 年多的时间就达到了 100 个，进入了「百抗」新时代（图五）。 图五 Nature Reviews Drug Discovery 20, 10 (2021) 上面提到的 100 个抗体并不是单纯经典的单克隆的裸抗体（naked antibody），其中也包括了抗体片段已经工程化修饰抗体的各种偶联形式。其中包括有抗体药物偶联（ADC
A Method to Isolate and Purify Human Bone Marrow Stromal Stem Cells
the rare STRO-1bright expressing fraction that contains all of the colony-forming BMSSC, based on their co-expression of a secondary cell surface marker, CD106 (VCAM-1).
A Method to Isolate, Purify, and Characterize Human Periodontal Ligament Stem Cells
on the expression of MSC-associated surface markers STRO-1 antigen, CD146 (MUC-18), CD29 (integrin β-1), CD44, and CD106 (VCAM-1). Although no single antibody demonstrates specificity for MSCs, isolation based on the expression of individual markers results
技术资料暂无技术资料 索取技术资料
